Finally, the phase III SPR1NT trial (NCT03505099) evaluated the efficacy and safety of onasemnogene abeparvovec in presymptomatic infants with spinal muscular atrophy (SMA) type 1 who have two copies of the SMN2 gene. This evidence concerns the gene SMN2 and spinal muscular atrophy, type 1.